Roger S. Newton

Dr. Newton is the founder and the board chair of Esperovax. He is also a fellow of the American Heart Association. Prior to starting Esperovax, he was co-founder, president and CEO of Esperion Therapeutics (ESPR) in 2008 after serving as senior vice president, Global R&D, for Pfizer Inc (2004-2008). Previously, Dr. Newton co-founded the original Esperion (1998-2004) until it was acquired by Pfizer in 2004 for $1.3 billion. He also chaired the Atherosclerosis Drug Discovery Team at Warner Lambert (1981-1993), during which he co-discovered and was the product champion of Lipitor; and was a Distinguished Research Fellow (1994-1998), actively preparing the Lipitor NDA and the product’s eventual worldwide launch.

Dr. Newton has been director of several life-science companies including Juventas Therapeutics, Inc. and Rubicon Genomics, Inc. In addition, he is a member of the National Advisory Boards for the Life Science Institute and Cardiovascular Center at the University of Michigan. Dr. Newton earned a Ph.D. in Nutrition from the University of California, Davis, an M.S. in Nutritional Biochemistry from the University of Connecticut, and a B.S. in Biology from Lafayette College.